| First in Human Study of M4344 in Participants With Advanced Solid Tumors (NCT02278250) | EMD Serono Research & Development Institute, Inc. | 2015-01-26 |
| A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, or Hepatocellular Carcinoma (NCT02423343) | Eli Lilly and Company | 2015-01-01 |
| Anti-Platelet and Statin Therapy to Prevent Cancer-Associated Thrombosis (NCT02285738) | Case Comprehensive Cancer Center | 2014-12-30 |
| Study of Orally Administered Enasidenib (AG-221) in Adults With Advanced Solid Tumors, Including Glioma, or Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation (NCT02273739) | Celgene | 2014-12-08 |
| Study to Evaluate the Safety and Efficacy of Gefitinib, in Subjects With EFGR Amplification Refractory Solid Tumors (NCT02447419) | Samsung Medical Center | 2014-12-03 |
| The Pilot Study Evaluate the Safety and Efficacy of Sirolimus in Patients With PIK3CA Mutation and/or PIK3CA Amplification Refractory Solid Tumors (NCT02449564) | Samsung Medical Center | 2014-11-24 |
| Pharmacokinetic Study of Docetaxel-PNP and Taxotere to Treat Patient With Advanced Solid Cancer (NCT02274610) | Samyang Biopharmaceuticals Corporation | 2014-11-01 |
| A Study: Pure CBD as Single-agent for Solid Tumor. (NCT02255292) | Hadassah Medical Organization | 2014-11-01 |
| Evaluate Time Associated With the Preparation & Administration of Denosumab/Pamidronate in Patients With Solid Tumors and Metastatic Bone Disease (NCT02101164) | Amgen | 2014-11-01 |
| MEK and MET Inhibition in Colorectal Cancer (NCT02510001) | University of Oxford | 2014-11-01 |
| Safety and Biomarker of OPB-111077 in Subjects With Advanced Solid Tumor (NCT02250170) | Korea Otsuka Pharmaceutical Co., Ltd. | 2014-10-23 |
| ALRN-6924 in Patients With Advanced Solid Tumors or Lymphomas (NCT02264613) | Aileron Therapeutics, Inc. | 2014-10-01 |
| A Dose-regimen Finding Study to Evaluate Safety, Tolerability, Pharmacokinetics and Activity of Oratecan in Subjects With Advanced Malignancies (NCT02250157) | Athenex, Inc. | 2014-09-05 |
| Safety and Tolerability of ASLAN001 in Combination With Cisplatin and 5-FU or Cisplatin and Capecitabine (NCT02648425) | ASLAN Pharmaceuticals | 2014-08-05 |
| Phase 1 Trial of Hu5F9-G4, a CD47-targeting Antibody (NCT02216409) | Gilead Sciences | 2014-08-01 |
| BGJ398 for Patients With Tumors With FGFR Genetic Alterations (NCT02160041) | Novartis Pharmaceuticals | 2014-07-24 |
| The Good Patient Study (NCT02199548) | St. Jude Children's Research Hospital | 2014-07-01 |
| Metronomic Therapy for Pediatric Patients With Solid Tumors at High Risk of Recurrence (NCT02446431) | Miller Children's & Women's Hospital Long Beach | 2014-07-01 |
| Study of MK-4166 and MK-4166 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4166-001) (NCT02132754) | Merck Sharp & Dohme LLC | 2014-06-27 |
| Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Advanced Solid Tumors (NCT02048709) | Genentech, Inc. | 2014-04-01 |
| Pharmacokinetics of Tivantinib in Subjects With Advanced Solid Tumors and Hepatic Impairment (NCT02150733) | Daiichi Sankyo | 2014-04-01 |
| MVX-ONCO-1 in Patients With Solid Tumor (NCT02193503) | Maxivax SA | 2014-03-01 |
| A Study to Assess the Efficacy and Safety of Eltrombopag as a Rescue of Isolated Chemotherapy-induced Thrombocytopenia (NCT02093325) | Chang Gung Memorial Hospital | 2014-03-01 |
| Safety Study of Vx006 Vaccine in Solid Tumor Patients (NCT02289196) | Vaxon Biotech | 2014-03-01 |
| Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-028/KEYNOTE-28) (NCT02054806) | Merck Sharp & Dohme LLC | 2014-02-17 |
| A Phase 1 TH-302 Mass Balance Trial (NCT02076230) | Merck KGaA, Darmstadt, Germany | 2014-02-01 |
| A Study of Vintafolide (MK-8109) in Participants With Advanced Solid Tumor (MK-8109-011) (NCT02049281) | Endocyte | 2014-02-01 |
| LGX818 for Patients With BRAFV600 Mutated Tumors (NCT01981187) | Pfizer | 2014-01-14 |
| First-in-Human Dose Escalation Trial in Subjects With Advanced Malignancies (NCT01971515) | EMD Serono | 2013-12-13 |
| Dose-Finding and Safety Study for Oral Single-Agent to Treat Advanced Malignancies (NCT02030067) | Processa Pharmaceuticals | 2013-12-01 |
| Indocyanine Green for Solid Tumors (NCT02280954) | University of Pennsylvania | 2013-11-01 |
| BP31510 (Ubidecarenone,USP) Nanosuspension for Intravenous Injection to Patients With Solid Tumors (NCT01957735) | BPGbio | 2013-10-01 |
| A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Activity of Oraxol in Subjects With Advanced Malignancies (NCT01967043) | Kinex Pharmaceuticals Inc. | 2013-10-01 |
| An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced Malignancies (NCT01929941) | Incyte Corporation | 2013-09-01 |
| LDE225 and Paclitaxel in Solid Tumors (NCT01954355) | Swiss Cancer Institute | 2013-09-01 |
| Phase 1 Study of PLX7486 as Single Agent in Patients With Advanced Solid Tumors (NCT01804530) | Plexxikon | 2013-08-01 |
| RX-5902 Treatment of Subjects With Triple Negative Breast Cancer (NCT02003092) | Rexahn Pharmaceuticals, Inc. | 2013-08-01 |
| A Dose-Escalation Study of GDC-0994 in Patients With Locally Advanced or Metastatic Solid Tumors (NCT01875705) | Genentech, Inc. | 2013-06-21 |
| Technology to Assess Vulnerable Older Adults With Cancer and Their Caregivers (NCT02041416) | City of Hope Medical Center | 2013-05-15 |
| Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-012/KEYNOTE-012) (NCT01848834) | Merck Sharp & Dohme LLC | 2013-05-07 |
| Study of Pembrolizumab (MK-3475) Monotherapy in Advanced Solid Tumors and Pembrolizumab Combination Therapy in Advanced Non-small Cell Lung Cancer/ Extensive-disease Small Cell Lung Cancer (MK-3475-011/KEYNOTE-011) (NCT01840579) | Merck Sharp & Dohme LLC | 2013-04-26 |
| A Japanese Phase 1 Trial of TH-302 in Subjects With Solid Tumors and Pancreatic Cancer (NCT01833546) | Merck KGaA, Darmstadt, Germany | 2013-04-18 |
| A Phase I Study of Subutinib Maleate Capsules on Toleration and Pharmacokinetics (NCT01806376) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2013-03-01 |
| Phase Ia/Ib Multicenter Trial of Mogamulizumab for Advanced or Recurrent Cancer. (NCT01929486) | Aichi Medical University | 2013-02-01 |
| Sorafenib and Topotecan in Refractory/Recurrent Pediatric Malignancies (NCT01683149) | H. Lee Moffitt Cancer Center and Research Institute | 2013-01-01 |
| Vemurafenib in Combination With Everolimus or Temsirolimus With Advanced Cancer (NCT01596140) | M.D. Anderson Cancer Center | 2012-12-18 |
| Phase 1/2 Study of Derazantinib (ARQ 087) in Adult Subjects With Advanced Solid Tumors With FGFR Genetic Alterations (NCT01752920) | Basilea Pharmaceutica | 2012-12-10 |
| A Phase 1 Study of MORAb-004 in Patients With Solid Tumor (Study: MORAb-004-J081-103) (NCT01773434) | Eisai Co., Ltd. | 2012-12-01 |
| A Study in Participants With Advanced Solid Tumors (NCT01682135) | Eli Lilly and Company | 2012-11-01 |
| Intravenously Administered Pegylated Liposomal Mitomycin-C Lipid-based Prodrug (PROMITIL) in Cancer Patients With Solid Tumors. (NCT01705002) | Lipomedix Pharmaceuticals Inc. | 2012-10-01 |
| EUS-FNA for Patients With Antithrombotic Agents (NCT01798654) | Hokkaido Pancreatobiliary Endoscopic Intervention Study Group | 2012-09-01 |
| A Dose Ascending Study of Gemcitabine Elaidate (CO-101) in Combination With Cisplatin (NCT01641575) | Clovis Oncology, Inc. | 2012-07-01 |
| Safety Study of KPT-330 (Selinexor) in Patients With Advanced or Metastatic Solid Tumor Cancer (NCT01607905) | Karyopharm Therapeutics Inc | 2012-06-18 |
| Interest of Routine Screening for Hepatitis B and C in Patients Receiving Chemotherapy for Solid Tumors (NCT02877589) | CHU de Reims | 2012-05-01 |
| A Trial of ABI-010 & ABI-007 in Patients With Advanced Non-Hematologic Malignancies (NCT00820768) | Celgene | 2012-04-01 |
| Immune Reconstitution in Oncology Patients Following Autologous Stem Cell Transplant (NCT01540175) | St. Jude Children's Research Hospital | 2012-03-01 |
| Vascular Dysfunction and Antiangiogenic Therapy (NCT02161978) | University Hospital, Angers | 2012-02-09 |
| Pazopanib and ARQ 197 for Advanced Solid Tumors (NCT01468922) | National Cancer Institute (NCI) | 2012-01-23 |
| Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors and Recurrent Malignant Lymphoma (NCT01473095) | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | 2011-11-01 |
| A Phase I Study of Epitinib(HMPL-813) in Patients With Advanced Solid Tumors (NCT02590952) | Hutchison Medipharma Limited | 2011-10-31 |
| Individualized Molecular Profiling for Allocation to Clinical Trials (IMPACT) Project (NCT02806388) | National Cancer Centre, Singapore | 2011-10-01 |
| Study of MLN2480 in Participants With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion in Participants With Metastatic Melanoma (NCT01425008) | Millennium Pharmaceuticals, Inc. | 2011-09-15 |
| A Phase I Study of E7050 in Subjects With Solid Tumors (NCT01428141) | Eisai Co., Ltd. | 2011-09-01 |
| Concurrent School Attendance And Cancer Therapy: The Experiences of 6-12 Year Old Pediatric Oncology Patients (NCT01383473) | St. Jude Children's Research Hospital | 2011-08-01 |
| A Drug Interaction Study to Assess the Effect of LY317615 on the Metabolic Pathway of Warfarin (NCT01388335) | Eli Lilly and Company | 2011-08-01 |
| Trial Evaluating the Safety and Pharmacokinetics of MFGR1877S in Patients With Advanced Solid Tumors (NCT01363024) | Genentech, Inc. | 2011-08-01 |
| A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0425 Administered With and Without Gemcitabine in Patients With Refractory Solid Tumors or Lymphoma (NCT01359696) | Genentech, Inc. | 2011-07-11 |
| Safety, Pharmacokinetics and Pharmacodynamics of BEZ235 Plus MEK162 in Selected Advanced Solid Tumor Patients (NCT01337765) | Pfizer | 2011-07-08 |
| Safety and Tolerability of DS-7423 in Subjects With Advanced Solid Malignant Tumors (NCT01364844) | Daiichi Sankyo | 2011-07-01 |
| Study of IMF-001 in Patients With Malignancies Expressing NY-ESO-1 (NCT01234012) | ImmunoFrontier, Inc. | 2011-05-01 |
| Study of an Investigational Drug, ASP3026, in Patients With Solid Tumors (NCT01401504) | Astellas Pharma Inc | 2011-05-01 |
| Screening for Vulnerability in the Elderly Supported at the Oscar Lambret Centre (NCT01415258) | Centre Oscar Lambret | 2011-03-01 |
| A Study of Tesetaxel Plus Capecitabine in Patients With Solid Tumors (NCT01315431) | Genta Incorporated | 2011-03-01 |
| A Phase I/II Trial of Crolibulin (EPC2407) Plus Cisplatin in Adults With Solid Tumors With a Focus on Anaplastic Thyroid Cancer (ATC) (NCT01240590) | National Cancer Institute (NCI) | 2011-01-26 |
| A Study of EMD525797 in Solid Tumor Patients in Japan (NCT01327313) | Merck KGaA, Darmstadt, Germany | 2011-01-01 |
| Phase I of OratecanTM in Combination With Capecitabine in Patients With Advanced Solid Malignancies (NCT01463982) | Hanmi Pharmaceutical Company Limited | 2010-12-01 |
| A Study of Belinostat in Combination With Warfarin in Patients With Solid Tumors or Hematological Malignancies (NCT01317927) | Spectrum Pharmaceuticals, Inc | 2010-12-01 |
| Prevalence of Creatinine Phosphokinase Increase in Patients With Solid Tumors Treated by Inhibitors of Tyrosine Kinases (NCT01248429) | Centre Oscar Lambret | 2010-11-01 |
| Individualized Stereotactic Body Radiotherapy of Liver Metastases (NCT01239381) | Massachusetts General Hospital | 2010-10-05 |
| Dose Escalation Study of ARQ 736 in Adult Subjects With Advanced Solid Tumors Harboring BRAF and/or NRAS Mutations (NCT01225536) | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | 2010-10-01 |
| A Study DHP107, a Novel Oral Paclitaxel Formulation, in Patients With Advanced Solid Tumours or Gastric Cancer (NCT02890511) | Daehwa Pharmaceutical Co., Ltd. | 2010-08-01 |
| Study of PEGPH20 With Initial Dexamethasone Premedication Given Intravenously to Patients With Advanced Solid Tumors (NCT01170897) | Halozyme Therapeutics | 2010-07-01 |
| Safety, Pharmacokinetics and Clinical Activity of Oral Rigosertib in Solid Tumors (NCT01168011) | Traws Pharma, Inc. | 2010-07-01 |
| A Study in Advanced Solid Tumors (NCT01063075) | Eli Lilly and Company | 2010-06-01 |
| Study of Angiocal® in Patients With Solid Tumors, Investigating Safety, Tolerability, Blood Concentration of Study Drug (NCT01141257) | Pieris Pharmaceuticals GmbH | 2010-05-01 |
| Pharmacokinetic Study of CPT-11, Raltegravir and Midazolam With Characterisation of UGT1A1 Genotype (NCT00808184) | National University Hospital, Singapore | 2010-04-01 |
| Study in Advanced Solid Tumors (NCT01099358) | Eli Lilly and Company | 2010-04-01 |
| A Dose-escalation Study in Subjects With Advanced Malignancies (NCT01072266) | Incyte Corporation | 2010-01-01 |
| A Study of MORAb-003 in Patients With Solid Tumor (NCT01049061) | Eisai Co., Ltd. | 2010-01-01 |
| Safety of 24-hour Infusion of ON 01910.Na in Combination With Gemcitabine in Advanced Solid Tumors (NCT01165905) | Traws Pharma, Inc. | 2010-01-01 |
| Safety Study of a Liposomal Docetaxel Formulation in Patients With Solid Tumors Who Have Failed Previous Therapies (NCT01041235) | Azaya Therapeutics, Inc. | 2009-12-01 |
| Safety Study of PLX108-01 in Patients With Solid Tumors (NCT01004861) | Daiichi Sankyo | 2009-10-01 |
| A Trial Of CVX-060, An Anti-Angiogenic COVX-Body, In Combination With Sunitinib In Patients With Advanced Renal Cell Carcinoma (NCT00982657) | Pfizer | 2009-09-01 |
| Dose Escalation, Safety and Pharmacokinetic Study of AVE8062 in Patients With Solid Tumors (NCT00968916) | Sanofi | 2009-09-01 |
| Pharmacokinetic Study of SYP-0704A and Taxotere to Treat Patient With Advanced Solid Cancer (NCT01336582) | Samyang Biopharmaceuticals Corporation | 2009-08-01 |
| Quantitative and Functional Study of TH17 Lymphocytes in Horton's Disease (HD) (NCT02065297) | Centre Hospitalier Universitaire Dijon | 2009-07-28 |
| Safety Profile, MTD, and PK Profile Studies of ABT-263 When Administered in Combination With Standard and Weekly Regimens of Docetaxel in Subjects With Cancer (NCT00888108) | Abbott | 2009-07-01 |
| RAD001 in Combination With CP-751,871 in Patients Wtih Advanced Sarcomas and Other Malignant Neoplasms (NCT00927966) | Suzanne George, MD | 2009-07-01 |
| Effect of Refnot on Immunity in Cancer Patients (NCT05898451) | Refnot-Pharm Ltd | 2009-06-04 |
| Safety Study to Evaluate KW-2450 in Subjects With Advanced Solid Tumor (NCT00921336) | Kyowa Kirin Co., Ltd. | 2009-06-01 |